HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy.

AbstractBACKGROUND:
Familial amyloidotic polyneuropathy (FAP) is an autosomal dominant inherited disease associated with a mutant form of the protein transthyretin (TTR). It is characterized clinically by the systemic deposition of amyloid fibrils resulting in organ dysfunction and, ultimately, death. The majority of TTR is produced in the liver, and transplantation of the liver has been shown to ameliorate this source of mutant TTR, arresting the progression of this fatal disease.
METHODS:
Thirteen patients with FAP have undergone successful liver transplant surgery at our center since 1992. The impact of liver transplantation on amyloid-related polyneuropathy, cardiovascular, and gastrointestinal dysfunction is reported in this study. Three patients who died before cardiovascular and neurological follow-up are excluded from the analysis.
RESULTS:
Ten of 13 patients (77%) remain alive an average of 49 months (range, 17-64 months) after transplantation. Three patients suffered sudden death, with autopsy documentation of amyloid deposits involving the conduction system of the heart. Liver transplantation was performed more quickly, required less blood, and a shorter postoperative hospital stay in these patients, compared with patients with cirrhosis. Neurological and nutritional symptoms improved in the majority of affected patients. Those patients with echocardiographic evidence of ventricular wall and valve thickening before transplantation progressed postoperatively despite neurologic improvement.
CONCLUSIONS:
Liver transplantation offers the only cure for the genetic defect causing FAP and appears to result in subjective and objective improvement in neurological dysfunction. Patients with preexisting cardiovascular abnormalities progress despite transplantation; therefore, consideration for combined heart-liver transplantation may be warranted in this subset of patients.
AuthorsE A Pomfret, W D Lewis, R L Jenkins, P Bergethon, S W Dubrey, J Reisinger, R H Falk, M Skinner
JournalTransplantation (Transplantation) Vol. 65 Issue 7 Pg. 918-25 (Apr 15 1998) ISSN: 0041-1337 [Print] United States
PMID9565095 (Publication Type: Clinical Trial, Journal Article)
Topics
  • Adult
  • Amyloid Neuropathies (genetics, physiopathology, therapy)
  • Cardiovascular System (physiopathology)
  • Disease Progression
  • Female
  • Humans
  • Liver Transplantation
  • Male
  • Middle Aged
  • Nervous System (physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: